Fiera Capital Corp decreased its holdings in shares of Insmed Incorporated (NASDAQ:INSM – Free Report) by 2.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 592,415 shares of the biopharmaceutical company’s stock after selling 13,112 shares during the quarter. Fiera Capital Corp’s holdings in Insmed were worth $43,246,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of INSM. Darwin Global Management Ltd. bought a new stake in Insmed during the second quarter worth approximately $237,076,000. Capital International Investors acquired a new position in Insmed in the 1st quarter valued at $43,973,000. Clearbridge Investments LLC bought a new position in Insmed in the 1st quarter worth $25,242,000. Farallon Capital Management LLC acquired a new position in Insmed during the 2nd quarter worth $38,056,000. Finally, Fred Alger Management LLC bought a new stake in Insmed during the second quarter valued at about $33,404,000.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. lifted their price objective on Insmed from $72.00 to $74.00 and gave the stock an “overweight” rating in a research note on Thursday, October 3rd. Truist Financial reiterated a “buy” rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a report on Friday, November 1st. Morgan Stanley boosted their target price on shares of Insmed from $60.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, July 12th. StockNews.com cut shares of Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. Finally, TD Cowen raised their price target on shares of Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $83.07.
Insider Transactions at Insmed
In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the sale, the insider now directly owns 100,100 shares in the company, valued at $7,157,150. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the transaction, the insider now owns 100,100 shares in the company, valued at $7,157,150. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now owns 106,134 shares of the company’s stock, valued at $7,951,559.28. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 78,882 shares of company stock valued at $5,765,446. Corporate insiders own 4.60% of the company’s stock.
Insmed Price Performance
INSM stock traded up $0.41 during trading on Friday, hitting $72.10. The company had a trading volume of 233,293 shares, compared to its average volume of 2,255,116. The company has a fifty day moving average price of $72.57 and a two-hundred day moving average price of $62.52. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53. The company has a market cap of $12.90 billion, a P/E ratio of -12.89 and a beta of 1.12. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.
Insmed (NASDAQ:INSM – Get Free Report) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. The business’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.10) EPS. Equities research analysts expect that Insmed Incorporated will post -5.52 earnings per share for the current fiscal year.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
See Also
- Five stocks we like better than Insmed
- Stock Market Sectors: What Are They and How Many Are There?
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- The Top 5 Performing S&P 500 Stocks YTD in 2024
- How to Find Undervalued Stocks
- L3Harris: Positioned for Gains With Trump’s Defense Policies
Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM – Free Report).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.